Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response

Elliyanti, Aisyah; Rusnita, Dewi; Afriani, Nita; Susanto, Yayi Dwina Billianti; Susilo, Veronica Y.; Setiyowati, Sri; Harahap, Wirsma Arif

doi:10.1007/s13139-019-00632-8

Cited by 9 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NIS is a transmembrane glycoprotein that contains 13 membrane-spanning segments and three N-linked carbohydrates. It resides in the basolateral membrane of epithelial thyroid cells [16][17][18][19][20]. Besides the thyroid cell, NIS is expressed by extra-thyroid tissues [20].…”

Section: Transport Radioiodinementioning

confidence: 99%

Radioiodine for Graves’ Disease Therapy

Elliyanti¹

2021

Graves' Disease

Self Cite

View full text Add to dashboard Cite

Radioiodine-131 (RAI) is an isotope of the chemical element iodine and is commonly used for hyperthyroidism, including Graves’ disease. It is given orally, and its concentration in the thyroid gland. The RAI transport involves a natrium iodide symporter (NIS) role that brings two cations sodium (Na+) and one anion of iodide (I-) across the membrane. The process is facilitated by the enzyme Na+/K+ ATPase. RAI is a beta (β) and gamma (γ) particles emitter. β particle is used for therapy and γ particle for imaging (theranostic). β particle inhibits cell growth by inducing cell death through apoptosis or necrosis of some of the sufficient thyroid cells. The aim of RAI therapy in Graves’ disease is to control hyperthyroidism and render the patient hypothyroidism. It is easier to manage patients with hypothyroidism with levothyroxine and fewer complications. This review will focus on RAI’s therapeutic approach in Graves’ disease, including patient preparation, selecting activity dose, adverse events, contraindication, controversies issues such as malignancy and fertility, the follow-up to ensuring the patient remains euthyroid or need a replacement therapy if they become hypothyroidism. RAI therapy is safe as definitive therapy and cost-effective for Graves’ disease therapy.

show abstract

Section: Transport Radioiodinementioning

confidence: 99%

Radioiodine for Graves’ Disease Therapy

Elliyanti¹

2021

Graves' Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…Breast cancer (BC) is the main cause of cancer-related mortality among females over the world [ 1 ]. Based on morphological and molecular observation, BC is classified into at least five subtypes: luminal A, luminal B, HER2 + , basal, and normal [ 2 ]. The symptoms of BC depend on the site of metastasis, of which depression, fatigue, insomnia, and pain are the frequent signs [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Long non‐coding RNA NEAT1 transported by extracellular vesicles contributes to breast cancer development by sponging microRNA-141-3p and regulating KLF12

Zhou

Wang

et al. 2021

Cell Biosci

View full text Add to dashboard Cite

Objective Breast cancer (BC) remains a public-health issue on a global scale. Long non-coding RNAs (lncRNAs) play functional roles in BC. This study focuses on effects of NEAT1 on BC cell invasion, migration and chemotherapy resistance via microRNA (miR)-141-3p and KLF12. Methods After extraction and identification of serum extracellular vesicles (EVs), NEAT1 expression in EVs was detected and its association with clinical characteristics of BC patients was analyzed. Besides, the gain-of function was performed to investigate the roles of NEAT1 and miR-141-3p in BC, and levels of NEAT1, miR-141-3p, KLF12 and MDR1 after EV treatment were detected by RT-qPCR and Western blot analysis. Furthermore, the in vitro findings were confirmed via lung metastases in nude mice. Results NEAT1 expression in serum EVs was high and related to lymph node metastasis, progesterone receptor, estrogen receptor and Ki-67 in BC patients. After EV treatment, NEAT1 and KLF12 levels were increased, miR-141-3p expression was decreased, the abilities of proliferation, invasion, migration and in vivo metastasis were enhanced, and the sensitivity of cells to cisplatin, paclitaxel and 5-fluorouracil was decreased. After NEAT1 interference, NEAT1 and KLF12 levels in BC cells treated with EVs were decreased, miR-141-3p expression was increased, cell proliferation, invasion, migration and in vivo metastasis were decreased, and drug resistance sensitivity was increased. NEAT1 can bind to miR-141-3p and upregulates KLF12 expression. Conclusions EVs inhibit the regulation of KLF12 by miR-141-3p by transporting NEAT1 to BC cells, thus promoting BC cell invasion, migration, and chemotherapy resistance.

show abstract

“…It resides in the thyroid in the basolateral membrane of epithelial cells and transports two cations of sodium (Na+) and one anion of iodide (I-) into the cells. This process is facilitated by an enzyme Na+/K+ ATPase [21], [22], [23].…”

Section: Introductionmentioning

confidence: 99%

Evaluating the Natrium Iodide Symporter Expressions in Thyroid Tumors

Elliyanti

Rustam

Tofrizal

et al. 2021

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Decreased Natrium iodide symporter (NIS) expression levels or diminished NIS targeting thyroid cancer cells’ plasma membrane leads to radioiodine-refractory disease. AIM: The aim of this study was to analyze the NIS expression in thyroid tumors. MATERIALS AND METHODS: The samples were thyroid tissues of patients who underwent surgery for a thyroid tumor. The tissues were processed for NIS protein expressions by immunohistochemistry (IHC) and Western blot (WB). Graves’ disease samples were used as positive controls. The samples were incubated without the primary antibody, and they were used as negative controls for IHC examination. Na+/K+ ATPase was a plasma membrane protein marker in the WB procedure. RESULTS: Twenty-nine samples were assessed for NIS protein. All of them showed the expression in the cytoplasm with intensity 1+ to 3+ with Allred score 3-8. Fourteen out of 29 cases (48.2%) showed NIS cytoplasm staining intensity ≥2+ consist of 10 papillary thyroid cancer (PTC), three follicular thyroid cancer, and one adenoma. Membrane staining was found in 2 samples of PTC (6.9%). Six samples (adenoma 1 sample, PTC 5 samples) showed NIS expression at membrane very weak (1+); they were considered as negative. NIS protein has several bands of ~ 80 kDa, ~ 62 kDa, and ~ 49 kDa. CONCLUSION: NIS expression in thyroid cancer mostly expresses in the cytoplasm instead of the membrane. NIS will play a functional role in the membrane to bring iodine across the membrane against the concentration. It can be the main reason for the lack of response of radioiodine in some differentiated thyroid cancers.

show abstract

Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response

Abstract: Submission ID: 1239273808File name: Jrnal_Internasional_dr._Aisyah.pdf (1.31M) Word count: 5623Character count: 29162

Cited by 9 publications

References 37 publications

Radioiodine for Graves’ Disease Therapy

Radioiodine for Graves’ Disease Therapy

Long non‐coding RNA NEAT1 transported by extracellular vesicles contributes to breast cancer development by sponging microRNA-141-3p and regulating KLF12

Evaluating the Natrium Iodide Symporter Expressions in Thyroid Tumors

Contact Info

Product

Resources

About